

2018 Washington State Interagency Opioid Working Plan

INTRODUCTION

Washington State is currently experiencing an opioid abuse and overdose crisis involving prescription opioids and heroin. In 2016, there were 694 opioid related deaths in Washington State, 382 individuals died from a prescription opioid overdose, 278 died from a heroin overdose, and 90 died from a fentanyl overdose. This high mortality is due to the increase in heroin overdose deaths even though prescription opioid overdose deaths have decreased. Younger people ages 15 to 34 years had higher numbers of heroin deaths while 45 to 64 year olds had higher prescription opioid deaths. According to the 2015 statewide survey of syringe exchange clients, 57% of those who inject heroin said they were “hooked on” prescription opiates before they began using heroin.¹

State government agencies, local health departments, professional groups and community organizations across Washington State have been actively building networks and capacity to reduce morbidity and mortality associated with opioids. In 2015, several agency members of the Department of Health’s Opioid Response Workgroup (formally the Unintentional Poisoning Workgroup) collaborated to develop a statewide opioid response plan. On September 30, 2016, Governor Jay Inslee signed [Executive Order 16-09](#), *Addressing the Opioid Use Public Health Crisis*, formally directing activities and state agencies in accordance with the Washington State Interagency Opioid Working Plan. In November 2016, agency members revised the WA State Opioid Response Plan to align with the executive order and activities directed by federal grants received in 2016.

The **Washington State Opioid Response Plan** outlines the goals, strategies and actions that are being implemented by a number of stakeholders across diverse professional disciplines and communities. This plan outlines both current efforts as well as new proposed actions to scale up response and will be regularly updated as the epidemic and response evolve over time.

PLAN OVERVIEW


The WA State Interagency Opioid Working Plan includes five priority goals:

1. Prevent opioid misuse and abuse.
2. Identify and treat opioid use disorder.
3. Prevent deaths from overdose.
4. Use data to detect opioid misuse/abuse, monitor morbidity and mortality, and evaluate interventions.
5. Collaborate with law enforcement to prevent illegal opioid use.



¹ 2015 Drug Injector Health Survey, University of Washington and Public Health – Seattle & King County.

Collectively, the strategies and specific actions are to reach populations most at risk, which include Alaskan Indian/ American Native, recently released persons from jails, youth, pregnant women, Medicaid, Workers Compensation, and rural populations.



COORDINATION AND IMPLEMENTATION

Partners from all sectors are driving implementation of these strategies forward. Included are state-level agencies and policy makers, professional associations, law enforcement, local health departments, tribal authorities, service providers, community coalitions and many others. The following stakeholders have expressed a particular interest and commitment to addressing opioid use and overdose prevention:

Federal and tribal partners:

- Center for Disease Control and Prevention (CDC)
- Substance Abuse and Mental Health Services Administration (SAMHSA)
- National Institute on Drug Abuse (NIDA)
- National Institutes of Health (NIH)
- Northwest High Intensity Drug Trafficking Area (NWHIDTA)
- US Attorney General’s Office (USAG)
- Tribal authorities

State partners:

- Department of Health (DOH), including
 - Dental Quality Assurance Commission (DQAC)
 - Board of Osteopathic Medicine and Surgery (BOMS)
 - Podiatric Medical Board (PMB)

Washington State Office of the Attorney General
Washington State Governor's Office
Washington State Toxicology Lab
Medical Quality Assurance Commission (MQAC)
Nursing Care Quality Assurance Commission (NCQAC)
Department of Labor & Industries (L&I)
Department of Social and Health Services (DSHS) Division of Behavioral Health and Recovery (DBHR)
Health Care Authority (HCA)
WA Poison Center (WAPC)
Office of Superintendent of Public Instruction (OSPI)
WA State Patrol (WSP)
Department of Corrections (DOC)
Administrative Office of the Courts (AOC)
Prevention Enhancement Policy Consortium
Bree Collaborative (Bree)
Agency Medical Directors' Group (AMDG)

Professional associations:

WA State Medical Association (WSMA)
WA State Hospital Association (WSHA)
WA State Nurses Association (WSNA)
WA Chapter-American College of Emergency Physicians (WA-ACEP)
WA State Pharmacy Association (WSPA)
WA State Dental Association (WSDA)
WA Society of Addiction Medicine (WSMA)
WA State Association of Police Chiefs (WASPC)
WA Association of Prosecuting Attorneys (WAPA)

Academic institutions:

University of Washington: Alcohol and Drug Abuse Institute (UW ADAI)
Center for Opioid Safety Education (COSE)
University of Washington Division of Pain Medicine
Washington State University
Eastern Washington Area Health Education Center (AEHC)

Local entities:

Local Health Jurisdictions
County drug and alcohol services coordinators
Drug treatment and mental health service providers
Syringe exchange programs
Community drug prevention coalitions and task forces

Four workgroups have been designated to coordinate the action steps under each of the four goals of the plan. Workgroups communicate and meet regularly to assess progress and identify emerging issues that require new actions. The lead contacts for each workgroup are:

- **Prevention Workgroup** (Goal 1):
Sarah Mariani, Division of Behavioral Health and Recovery mariase@dshs.wa.gov
Jaymie Mai, Department of Labor & Industries maij235@lni.wa.gov
- **Treatment Workgroup** (Goal 2):
Jessica Blöse, Division of Behavioral Health and Recovery blösejk@dshs.wa.gov
- **Naloxone Workgroup** (Goal 3):
Alison Newman, Alcohol and Drug Abuse Institute alison26@uw.edu
- **Data Workgroup** (Goal 4):
Cathy Wasserman, Department of Health Cathy.Wasserman@doh.wa.gov
- **Criminal Justice Workgroup** (Goal 5):
Ahney King, Division of Behavioral Health and Recovery ahney.king@dshs.wa.gov

GOALS AND STRATEGIES

GOAL 1: Prevent inappropriate opioid prescribing and prevent opioid misuse and abuse.			
STRATEGY 1: Promote use of best practices among health care providers for prescribing opioids for acute and chronic pain.	Lead Party	Status	EO*
Educate health care providers on the 2015 Agency Medical Directors' Group Interagency Guideline for Prescribing Opioids for Pain, the Washington Emergency Department Opioid Prescribing Guidelines and the CDC Guideline for Prescribing Opioids for Chronic Pain to ensure appropriate opioid prescribing.	L&I DBHR	Ongoing	Goal 1, section 1
Promote the use of the Prescription Drug Monitoring Program (PMP), including use of delegate accounts, among health care providers to help identify opioid use patterns, sedative co-prescribing, and indicators of poorly coordinated care/access.	DOH, Bree	Ongoing	
Train, coach and offer consultation with providers on guideline-adherent opioid prescribing and non-opioid alternatives for pain management (e.g., TelePain video conferencing and opioid consultation hotline).	HCA, DOH, UW	Ongoing	Goal 1, section 3
Collaborate with UW Department of Family Medicine to provide academic detailing and practice coaching to clinics in Washington State.	DOH	Ongoing	
Collaborate with professional associations, teaching institutions, boards and commissions and insurers to reduce unnecessary opioid prescribing for acute pain conditions especially in the adolescent population.	L&I, Bree	Ongoing	
Enhance medical, nursing, and physician assistant school curricula on pain management, PMP, and treatment of opioid use disorder	DOH	Ongoing	
Require health plans contracted with the Health Care Authority to follow guideline best practices on opioid prescribing.	Bree, HCA	Ongoing	
Explore innovative methods and tools to deliver evidence-based alternatives and other promising practices to reduce overreliance on opioids while improving access to care and health outcomes for pain treatment, such as non-opioid pain therapies and collaborative care models.	HCA, L&I	Ongoing	Goal 1, section 3 Goal 2, section 4
STRATEGY 2: Raise awareness and knowledge of the possible adverse effects of opioid use, including overdose, and focus on reducing the stigma of opiate use disorder.	Lead Party	Status	EO*
Distribute counseling guidelines and other tools to pharmacists, chemical dependency professionals, and health care providers and encourage them to educate patients on prescription opioid safety (storage, disposal, overdose prevention and response). http://stopoverdose.org/docs/OpioidOverdose.pdf doh.wa.gov/YouandYourFamily/PoisoningandDrugOverdose/TakeAsDirected/ForPainPatients.aspx	DBHR, ADAI	Ongoing	Goal 1, section 2

Provide targeted and culturally appropriate health education to opioid users and their social networks through print and web-based media	ADAI DBHR	Ongoing	Goal 2, section 2
Promote accurate consistent and culturally appropriate messaging about opioid safety and addiction.	DOH, ADAI	Ongoing	Goal 1, section 2
As available, promote national social marketing campaigns on the potential harms of prescription medication misuse and abuse and secure home storage for local application.	DOH, DBHR	Ongoing	
Conduct an inventory of existing patient materials on medication safety for families and children. Develop new materials as needed as tools for health care providers and parents.	DBHR	Ongoing	
STRATEGY 3: Prevent opioid misuse in communities, particularly among youth.	Lead Party	Status	EO*
Work with community coalitions to implement strategies to prevent youth prescription drug misuse from the Substance Abuse Prevention and Mental Health Promotion Five-Year Strategic Plan. http://www.theathenaforum.org/sites/default/files/SPE%20Strategic%20Plan%20-%20Final%20-%20Posted%20to%20Athena%2011.29.17.pdf	DBHR	Ongoing	Goal 3, Section 1
Provide prevention funds from which mini grants can be awarded to organizations and coalitions to implement key actions of the State Opioid Response Plan.	DBHR	Ongoing	
STRATEGY 4: Promote safe home storage and appropriate disposal of prescription pain medication to prevent misuse.	Lead Party	Status	EO*
Educate patients and the public on the importance and ways to properly store and dispose of prescription pain medication.	DBHR	Ongoing	Goal 1, Section 2
Promote the use of home lock boxes to prevent unintended access to medication.	DBHR	Ongoing	
Explore funding and regulatory enhancements to sustain and evaluate Drug Take Back programs.	DBHR	Ongoing	Goal 1, Section 2
GOAL 2: Link individuals with opioid use disorder to treatment support services.			
STRATEGY 1: Build capacity of health care providers to recognize signs of possible opioid misuse, effectively screen for opioid use disorder, and link patients to appropriate treatment resources.	Lead Party	Status	EO*
Educate providers across all health professions on how to recognize signs of opioid misuse among patients and how to use appropriate tools to screen for opioid use disorder.	HCA	Ongoing	
Build skills of health care providers to have supportive patient conversations about problematic opioid use and treatment options.	HCA, ADAI	Ongoing	

Strengthen addiction education in all health teaching institutions and residency programs.	HCA and ADAI	Active	
Give pharmacists tools on where to refer patients who may be misusing prescription pain medication.	HCA, Pharmacy Commission	Ongoing	
STRATEGY 2: Expand access to and utilization of opioid use disorder medications in communities.	Lead Party	Status	EO*
Separate buprenorphine from existing daily reimbursement rate for opioid treatment program providers and create a differential reimbursement rate for buprenorphine.	DBHR, HCA	Completed	
Increase services to connect people to effective treatment via the WA State Recovery Helpline including dedicated staffing, a near real time buprenorphine directory, and informational webpage. Supported with funds from DOH PFS grant and other partners.	ADAI	Ongoing	
Identify policy gaps and barriers that limit availability and utilization of buprenorphine, methadone, and naltrexone and develop policy solutions to expand capacity.	HCA DBHR, ADAI	Ongoing	
Provide technical assistance to county health officers, prosecutors and other stakeholders to advocate for expanded local access to opioid use disorder medications.	DOH, ADAI	Ongoing	
Build up supports (e.g., case management capacity) to help medical providers and staff implement and sustain buprenorphine treatment. <ul style="list-style-type: none"> Consider use of “hub and spoke” and Center of Excellence models. Leverage funding and human resources for telemedicine support. 	DBHR, ADAI	Ongoing	Goal 2, Section 2
Increase the number of opioid treatment programs (existing or new) that offer methadone and/or buprenorphine.	DBHR	Ongoing	Goal 2, Section 2
Pilot new models of community-based buprenorphine to support recovery and prevent overdose (e.g., stabilizing individuals on buprenorphine without mandates counseling, urinalysis, etc.)	ADAI	Ongoing	Goal 2, Section 2
Encourage family medicine, internal medicine, OB/GYN residency programs to train residents on care standards/medications for OUD.	ADAI	Ongoing	
Eliminate discrimination in residential and recovery support programs that do not allow residents to be on legally prescribed and buprenorphine and/or methadone.	DBHR, HCA	Ongoing	
Expand care navigation to engage and retain people on opioid treatment medications in community (syringe exchange, outreach, jail) and service agency settings	DBHR, ADAI	Ongoing	
Expand peer-based recovery support/coach programs within medication-assisted treatment programs.	DBHR	Pending	

Identify critical workforce gaps in and develop new initiatives to attract and retain skilled professionals in the field.	DBHR DOH	Ongoing	
---	-------------	---------	--

STRATEGY 3: Increase capacity of syringe exchange programs (SEP) to effectively provide overdose prevention and engage clients in support services, including housing.	Lead Party	Status	EO*
Regularly collect primary data to document current health needs of individuals who inject heroin and other opioids.	ADAI	Ongoing	
Frequently map SEP services and funding levels to determine critical gaps and unmet levels of need among people who inject drugs.	DOH, ADAI	Ongoing	
Identify and leverage diversified funding for SEPS to adequately provide supplies, case management, health engagement services, and comprehensive overdose prevention education.	DOH, DBHR, ADAI	Ongoing	Goal 2, Section 2
Provide technical assistance to local health jurisdictions and community-based organizations to organize or expand syringe exchange and drug user health services.	DOH, DBHR, ADAI	Ongoing	Goal 2, Section 2
STRATEGY 4: Identify and treat opioid abuse during pregnancy to reduce withdrawal symptoms in newborns and support maternal recovery.	Lead Party	Status	EO*
Add overdose education (including how and where to obtain naloxone) to care recommendations in the <i>Substance Use during Pregnancy: Guidelines for Screening and Management</i> best practice guide.	DOH	Completed	
Support jails in ensuring pregnant inmates have ready access to agonist treatment medications and seamless handoffs to medications upon release	DOH, DBHR, HCA	Completed	
Educate maternity care providers to identify and refer for treatment those women with opioid use disorders who are pregnant or parenting. Disseminate the <i>Substance Use during Pregnancy: Guidelines for Screening and Management</i> best practice guide.	DOH, DBHR	Ongoing	
Disseminate the <i>WA State Hospital Association Safe Deliveries Roadmap</i> standards to health care providers to improve screening and referral of substance use disorders in pre-pregnancy, pregnancy, and post-partum care.	WSHA, DOH	Ongoing	
Create a DBHR/WSHA partnership to provide SBIRT training to obstetric and primary care clinicians.	DBHR, WSHA, DOH	Ongoing	
Add overdose education (including how and where to obtain naloxone) to the Parent-Child Assistance Program website of host agencies.	DBHR	Ongoing	
Educate pediatric and family medicine providers to recognize and appropriately refer newborns with Neonatal Abstinence Syndrome.	DOH	Ongoing	

GOAL 3: Intervene in opioid overdoses to prevent death.			
STRATEGY 1: Educate individuals who use heroin/illicit opioids and/or prescription opioids, and those who may witness an overdose, on how to recognize and appropriately respond to an overdose.	Lead Party	Status	EO*
Develop and/or update information and educational materials on overdose risks, recognition and response on www.stopoverdose.org .	ADAI	Ongoing	
Provide technical assistance to jails, prisons, and drug courts to implement overdose education and naloxone for people under criminal sanctions.	ADAI	Ongoing	
Provide technical assistance to first responders/law enforcement on opioid overdose response training and naloxone programs.	ADAI	Ongoing	
Educate law enforcement, prosecutors and the public about the Good Samaritan Overdose Laws.	ADAI	Ongoing	
Collaborate with the BHOs/FIMCs to provide residential, outpatient and withdrawal management programs with guidelines, training and tools to provide overdose prevention education to all clients.	DBHR	Ongoing	
Assist emergency departments to develop and implement protocols on providing overdose education and take-home naloxone to individuals seen for opioid overdose.	ADAI, ACEP	Ongoing	
STRATEGY 2: Make system-level improvements to increase availability and use of naloxone.	Lead Party	Status	EO*
Establish standing orders in counties to authorize community-based naloxone distribution and lay administration.	DOH	Ongoing	
Create a centralized naloxone procurement and distribution process at the state level.	AMDG, DBHR	ongoing	
Scale up and sustain naloxone distribution through syringe exchange programs.	DOH, DBHR	Ongoing	
Increase the number of pharmacies offering naloxone.	WSPA, COSE	Ongoing	
Evaluate the utilization and health impacts of naloxone administered by police, fire department, and emergency medical technicians.	DOH, ADAI	Ongoing	
Promote co-prescribing of naloxone for pain patients as best practice per AMDG guidelines. Add prompts to PMP to encourage providers to prescribe naloxone to patients on high doses of opioids.	DOH, L&I	Ongoing	
GOAL 4: Use data and information to detect opioid misuse/abuse, monitor morbidity and mortality, and evaluate interventions.			

STRATEGY 1: Improve PMP functionality to document and summarize patient and prescriber patterns to inform clinical decision-making.	Lead Party	Status	EO*
Track PMP reporting frequency by pharmacies and ensure compliance of new requirement of daily reporting to reduce the lag between opioid dispensing and viewing the prescription in the PMP from 10 to 4 business days.	DOH	Ongoing	
Provide easy access to the PMP data for providers through electronic medical record systems.	DOH	Ongoing	
Reduce current policy and technical barriers amongst border states to enable sharing of PMP data with border states.	DOH	Ongoing	
Consider providing MED calculations within the PMP for chronic opioid patients.	DOH	Ongoing	
Encourage health care systems to connect to the PMP through the statewide electronic health information exchange.	DOH	Ongoing	
Explore sharing PMP data for Medicaid clients via the clinical data repository.	HCA, DOH	Pending	Goal 4, section 2
Share Medicaid client PMP data linked with claims data with managed care organizations so that patients at risk for overdose can be enrolled in case management programs.	HCA	Ongoing	
Explore use of PMP data for overdose notification to providers.	DOH	Pending	
STRATEGY 2: Utilize the PMP for public health surveillance and evaluation.	Lead Party	Status	EO*
DOH completed development of metrics with BREE	DOH	Completed	
Analyze linked PMP and overdose death data to determine relationships between prescribing, patient risk behavior, and overdoses.	DOH	Ongoing	
Produce population-level PMP reports on controlled substance prescribing practices. Disseminate results to individual counties.	DOH, ADAI	Ongoing	
Produce measures using PMP data to monitor prescribing trends and assess the impact of interventions on prescribing practices.	DOH	Ongoing	
Refine a mapping tool to disseminate PMP measures to partners.	DOH	Ongoing	
Explore different ways to provide data to prescribers and other entities on prescribing practices	DOH	Pending	
Determine patient and prescriber patterns of buprenorphine use and prescribing to: develop standardized metrics, document care patterns, determine impacts of system level interventions to increase capacity and implement new models of care including Opioid Treatment Networks/Hub & Spoke and treatment on demand models.	TBD	Pending	

Fund State Toxicology lab through CDC ESOOS grant to reduce the processing time of opioid toxicology reports	DOH	Ongoing	
STRATEGY 3: Continue and enhance efforts to monitor opioid use and opioid-related morbidity and mortality.	Lead Party	Status	EO*
Monitor data on opioid-related hospitalizations and deaths, opioid misuse, neonatal abstinence syndrome (DOH), treatment admissions (DBHR) and police evidence data (ADAI). Publish Information Briefs to promote evidence-based policymaking and service planning.	ADAI	Ongoing	
Improve the quality of data on death certificates.	DOH	Ongoing	
Develop a plan to use new data sources (e.g., statewide ER and EMS data) to support public health surveillance and impact assessment.	DOH, ADAI	Ongoing	
Improve timeliness of fatal and non-fatal overdose, emergency department and hospitalization data.	DOH	Ongoing	
STRATEGY 4: Monitor progress towards goals and strategies and evaluate the effectiveness of our interventions.	Lead Party	Status	EO*
Evaluate policy interventions for effectiveness and impact (e.g., connecting the PMP to the Emergency Department Information Exchange, pain management rules).	UW, DOH	Ongoing	Goal 4, section 4
Evaluate projects implemented under the CDC Prescription Drug Overdose Prevention for States Grant.	DOH	Ongoing	

GOAL 5: Partner with law enforcement to prevent illicit opioid use.

STRATEGY 1: Decrease the supply of illegal opioids.	Lead Party	Status	EO*
Partner with law enforcement to decrease illicit distribution of opioids.	DOH	Ongoing	
Educate local law enforcement on handling reports of illegal prescribing. If necessary, develop and monitor an anonymous tip line for health providers, pharmacists and the public to report unlawful prescribing practices.	WSP	Pending	
Increase the number of investigations on unlawful prescribing practices. Coordinate with law enforcement if prescribers are arrested so that patients can be adequately managed.	WSP	Pending	
Educate law enforcement about PMP and how it works.	DOH	Pending	
STRATEGY 2: Expand access to and utilization of opioid use disorder medications in the juvenile and adult criminal justice system.	Lead Party	Status	EO*

Train and provide technical assistance to criminal justice professionals to endorse and promote opioid agonist and antagonist therapies for people under criminal sanctions.	DBHR, ADAI	Ongoing	
Optimize access to Substance Use Disorder services for offenders who have been released from prison and jails into the community and for offenders living in the community under correctional supervision.	DBHR, HCA, ADAI	Ongoing	Goal 2, Section 3
Work with jails and prisons to initiate and/or maintain incarcerated persons on medications for opioid use disorder.	DBHR, HCA, ADAI	Ongoing	
Incentivize state-funded drug and other therapeutic courts to provide access to a full range of medications for opioid use disorder.	DBHR	New	
Develop alternatives to incarceration and diversion opportunities for individuals who may have criminal justice system involvement offenses who have any substance use disorder. Using the Sequential Intercept Model developed by the SAMHSA GAINS Center to provide diversion opportunities at all intercepts.	TBD	New	
Provide training for providers and mid-level providers on inductions for antagonist and agonist and start treatment for OUD in the jail and prisons.	TBD	New	
Collaborate with other state agencies, local justice system, and community provider to overcome the two biggest barriers, housing and transportation, to successful recovery.	TBD	New	
Develop uniform data collect and data sharing with other state agencies, local justice system, prison and jails.	TBD	New	
To further develop collaboration between all stakeholders, host a symposium or other round table discussion as a follow-up to June 15-16, 2017, Summit on Reducing the Supply of Illegal Opioids in Washington	TBD	New	
Write an 1115 federal waiver that would allow medical service can be reimbursed as a Medicaid services, including medication assisted treatment, for individuals who are incarcerated.	TDB	New	